



Immunopathogenesis and Novel Therapeutics Strategies of Systemic Lupus Erythematosus 2.0

Guest Editors:

Prof. Dr. Marzena Olesińska

Department of Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation, 02-637 Warsaw, Poland

Prof. Dr. Przemysław J Kotyla

Department of Internal Medicine Rheumatology and Clinical Immunology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-635 Katowice, Poland

Deadline for manuscript submissions:

closed (30 November 2024)

Message from the Guest Editors

Dear Colleagues,

Systemic lupus erythematosus (SLE) is a connective tissue disease. Understanding the SLE pathogenic background and disease-driving mechanisms will contribute to the development of novel therapeutic strategies. In the course of SLE, several immunological phenomena may be observed, such as the loss of tolerance to self-antigens, autoreactive T- and B-cell activation, the synthesis of autoantibodies, and the activation of interferon.

This Special Issue focus on understanding the immunopathological mechanisms, biomarkers, and novel therapeutic strategies in SLE. Topics include, but are not limited to, the following:

- The genetic background of SLE;
- The epigenetic regulation of lupus;
- Cellular and molecular mechanisms in lupus;
- The role of cytokine networks in lupus progression;
- Innate and adaptive immunity in SLE;
- The role of immunocompetent cells in lupus pathogenesis and disease mechanisms;
- The role of interferon and interferon signature in lupus pathogenesis;
- Novel lupus biomarkers in SLE diagnosis and monitoring disease activity;
- Novel therapeutics and new treatment strategies for lupus.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. José L. Quiles

Department of Physiology,
Institute of Nutrition and Food
Technology “Jose Mataix”,
Biomedical Research Center,
University of Granada, Avda.
Conocimiento s/n, 18100 Armilla,
Granada, Spain

Message from the Editor-in-Chief

The *International Journal of Molecular Sciences (IJMS)* is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, and molecular biophysics. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Contact Us

*International Journal of Molecular
Sciences* Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/ijms
ijms@mdpi.com
X@IJMS_MDPI